Back to results
US 5,854,245 AGranted
Fibrinogen receptor antagonists
AssigneeMerck & Co., Inc.
InventorsMark E. Duggan, Melissa S. Egbertson, George D. Hartman, Steven D. Young, Nathan C. Ihle
Life of this patent
Estimating the term…
Abstract
Fibrinogen receptor antagonists having the structure X--Y--Z--A--B and pharmaceutically acceptable salts, wherein X is a 5, 6 or 7 membered aromatic or nonaromatic ring, and Y is a 5 or 6 membered aromatic ring, e.g., ##STR1##
Claims10
A compound having the formula
- X--Y--Z--A--B
- or a pharmaceutically acceptable salt,
- wherein
- X and Y form the fused ring systems:
- ##STR176## z is ##STR177## A is ##STR178## and B is --OCH.sub.2 CO.sub.2 H, --OCH.sub.2 CO.sub.2 CH.sub.2 C(O)NHCH.sub.3, --OCH.sub.2 CO.sub.2 CH.sub.2 C(O)N(CH.sub.2 CH.sub.3).sub.2, --OCH.sub.2 CO.sub.2 CH.sub.2 CH.sub.3, --CH.sub.2 CH.sub.2 CO.sub.2 H, --CH.sub.2 COOH, --OCH(CH.sub.3)CO.sub.2 H, or --OCH(CH.sub.3)CO.sub.2 CH.sub.2 CH.sub.3.
2 more elements
A compound selected from the group consisting of
- 3-(4-(4-piperazin-1-ylphenylcarbonylamino)phenyl) propanoic acid,
- 2-(4-(4-Piperazinyl-1-yl)phenylcarbonylamino)phenoxy) acetic acid,
- Ethyl 2-(4-(4-(1-piperazinyl)phenylcarbonylamino)phenoxy)acetate, hydrochloride,
- 2-(5-(4-(1-Piperazinyl)phenylcarbonylamino)indol-1-yl) acetic acid,
- 3-(3-(4-Piperazin-1-ylphenyl)carbonylamino)phenyl) propanoic acid,
- Ethyl 2-(4-(4-(piperazin-1-yl)phenylcarbonylamino) phenoxy)propanoate
- 2-(4-(4-(Piperazin-1-yl)phenylcarbonylamino)phenoxy) propionic acid,
- 2-(4-(((2-Piperazin-1-yl)pyridin-5-yl)carbonylamino)phenoxy)acetic acid,
- 2-(4-(5-(4-(1,1-Dimethylethoxycarbonyl)-piperazin-1-yl)-2-thienylcarbonylam ino)-3-methylphenoxy)-acetic acid,
- 4-((2,3,4,5-tetrahydropyrazino-1,2-a!indole-8-yl)carbonylamino)-3-methylph enoxyacetic acid, and
- or a pharmaceutically acceptable salt thereof.
8 more elements
A method for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising treating the mammal in need thereof with a fibrinogen binding inhibitory amount of a composition of claim 19.
Dependencies are inferred from the claim text.